Search
Vildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigationalVildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are i...
Categories: P-glycoprotein substratesLanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analo...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsTranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and i...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalBrentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigationalFidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-mem...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsGlycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2D6 InhibitorsPomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand nam...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP3A InhibitorsSofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalSofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-strand...
Categories: P-glycoprotein substrates